Several derivatives of vancomycin are currently being developed, including oritavancin and dalbavancin (both lipoglycopeptides).  Possessing longer half-lives than vancomycin, these newer candidates may demonstrate improvements over vancomycin due to less frequent dosing and activity against vancomycin-resistant bacteria.